SCHEMBL1358064

SCHEMBL1358064

CC(C)NC(=O)c1coc2c(C(C)(C)C)cc(-c3ccc[nH]c3=O)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.38
ABL1 P00519 1/20 0.36
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
MCL1 Q07820 1/20 0.32
BRD4 O60885 1/20 0.32
CREBBP Q92793 1/20 0.32
DYRK1A Q13627 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
CYP1A2 P05177 1/20 0.32
SMYD3 Q9H7B4 1/20 0.32
POLB P06746 1/20 0.31
METAP2 P50579 1/20 0.31
EIF2S1 P05198 2/20 0.31
EIF2AK3 Q9NZJ5 2/20 0.31
F2 P00734 1/20 0.31
F11 P03951 1/20 0.31
KLKB1 P03952 1/20 0.31
CTRB1 P17538 1/20 0.31
CTRL P40313 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359292 0.89 CYP3A4 (0.38) CYP3A4ABL1CREBBPF2F11
SCHEMBL1359874 0.87 POLB (0.38) CYP3A4ABL1MAOBDYRK1ASMN1; SMN2
SCHEMBL1360340 0.86 NAPRT (0.40) CYP3A4ABL1MAOBCREBBPF2
SCHEMBL1359878 0.85 ABL1 (0.41) CYP3A4ABL1MAOBMEN1KMT2A
SCHEMBL1358066 0.84 MAOB (0.42) CYP3A4ABL1MAOBPOLBF2
SCHEMBL1360734 0.84 MAOB (0.40) CYP3A4MAOAMAOBKDM4EKMT2A
SCHEMBL1358139 0.83 KMT2A (0.37) CYP3A4ABL1SMN1; SMN2POLBKDM4E
SCHEMBL1359911 0.82 MAPT (0.34) CYP3A4SMN1; SMN2CYP1A2POLBMEN1
SCHEMBL1359385 0.82 MAPT (0.36) CYP3A4BRD4SMN1; SMN2POLBKDM4E
SCHEMBL1359870 0.82 CYP3A4 (0.34) CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US claimed
EP-2334662-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. Hoffmann-La Roche AG (CH) 2011-06-22 EP claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS CYP3A4 713/4885ABL1 641/4885MAOA 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.